Paragonix to Showcase Extensive Organ Transplant Research at the 45th Annual Meeting of the International Society of Heart and Lung Transplantation

Abstracts to be presented at the 2025 ISHLT Annual Meeting and Scientific Sessions will emphasize the expanding clinical evidence demonstrating the positive post-transplant impact of Paragonix's advanced organ preservation devices on patient outcomes.

WALTHAM, Mass.--(BUSINESS WIRE)--Paragonix Technologies, Inc., a pioneer in organ transplant products and services, is honored to announce the forthcoming release of new clinical data supporting the use of FDA-cleared and CE marked controlled hypothermic preservation devices and transplant services. These presentations compare and analyze post-transplant outcomes of patients, presented by a multi-center panel of clinical investigators representing the GUARDIAN Clinical Registries at the 45^th ISHLT Annual Meeting and Scientific Sessions, located at the Hynes Convention Center in Boston, MA from April 27-30, 2025.

Clinical investigators will be sharing data and research related to Paragonix heart and lung devices (Paragonix SherpaPak^®, BAROguard^®, and LUNGguard^®) in five oral presentations and four posters throughout the conference, including:

• Presentation: Lung Preservation at Controlled 4-8°C for Extended Criteria Donors Improves Outcome After Transplantation
  • April 27, 2025, 3:00 PM - 3:08 PM - Ballroom B
• Presentation: Constant Airway Pressure Management System Leads to Improved Donor Lung Outcomes: Analysis of Ischemic Times >8 Hours
  • April 27, 2025, 4:42 PM - 4:50 PM - Rooms 302-304-306
• Presentation: Impact of Controlled Hypothermic Preservation of Donor Hearts at 4-8°C on Late Post-Transplant Cardiac Allograft Vasculopathy
  • April 28, 2025, 3:00 PM - 3:08 PM - Ballroom B
• Presentation: Controlled Hypothermic Preservation at 4-8°C Reduces Re-Hospitalization After Heart Transplantation Compared to Ice: Results from the Guardian Registry
  • April 28, 2025, 3:24 PM - 3:32 PM - Ballroom B
• Presentation: Donor Heart Preservation at 4-8°C Using Moderate Hypothermic Donor Heart Preservation Improves 4-year Survival in the US Guardian-Heart Registry
  • April 28, 2025, 3:48 PM - 3:56 PM - Ballroom B
• Presentation: Global Outcomes with Extended Criteria Donors When Preserved at 4-8°C: An Updated Analysis of the International GUARDIAN Heart Registry
  • April 29, 2025, 3:12 PM - 3:20 PM - Rooms 302-304-306
• Mini Presentation: Real-World Outcomes Using Controlled Moderate Hypothermia at 4-8°C for Lung Transplant: An Update from the Guardian-Lung Registry
  • April 29, 2025, 5:18 PM - 5:22 PM - Ballroom B
• Mini Presentation: Outcomes Following Donation After Circulatory Death: Comparing Normothermic Regional Perfusion with Controlled 4-8°C Hypothermic Preservation and Extracorporeal Normothermic Perfusion
  • April 29, 2025, 5:24 PM - 5:28 PM - Ballroom A
• Poster: Controlled Moderate Hypothermic Storage at 4-8°C for the Preservation of Donor Lungs from Donations After Circulatory Death
  • April 29, 2025, 4:30 PM - 5:30 PM - Poster Hall
• Poster: First Pediatric Use of Donor Lung Preservation System That Maintains Both Moderate Hypothermia and Constant Airway Pressure Management in High-Risk Lung Transplantation
  • April 29, 2024, 4:30 PM - 5:30 PM - Poster Hall

Additionally, Paragonix will be hosting two industry symposiums:

• Lung Symposium - Revolutionary Measures: Transformative Innovations Reshaping Lung Preservation
  • Monday, April 28^th, 11:45 AM to 12:45 PM - Room 311
• Heart Symposium - Mounting Evidence: Multifaceted Impact of Advanced Heart Preservation
  • Tuesday, April 29^th, 11:45 AM to 12:45 PM - Room 302/304/306

Both events will feature panels of leading surgeons and investigators of the GUARDIAN Registries as they explore the scientific foundation of advanced organ preservation and examine the associated impact on patient outcomes.

"We are excited to see the extensive research being presented at this year’s conference, which underscores the advancement of groundbreaking organ preservation technologies," said Dr. Lisa Anderson, President of Paragonix. "It is truly an honor to highlight and celebrate the important work of our distinguished colleagues, whose contributions are reshaping the future and elevating the standards of care in organ transplantation."

To visit the Paragonix Technologies exhibit and meet members of their team at ISHLT, visit booth #317. For more information about Paragonix, visit www.paragonix.com.

About Paragonix Technologies

Paragonix Technologies is a leading developer, manufacturer, and service provider in the organ transplant industry, establishing a novel approach to organ preservation.

A Getinge company, Paragonix Technologies provides Advanced Organ Preservation (“AOP”) devices that safeguard donor organs during the journey between donor and recipient patients. Their FDA-cleared and CE-marked devices incorporate clinically proven and medically trusted cold preservation techniques that allow unprecedented physical and thermal protection to the organ during transit. All Paragonix AOP devices are natively integrated with a novel digital app, delivering real-time organ tracking data and monitoring logistics for transplant teams seeking a secure and centralized solution. For more information, visit www.paragonix.com.

About Getinge

With a firm belief that every person and community should have access to the best possible care, Getinge provides hospitals and life science institutions with products and solutions aiming to improve clinical results and optimize workflows. The offering includes products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile processing and life science. Getinge employs approximately 12,000 people worldwide and the products are sold in more than 135 countries.

Connect with us on LinkedIn: Paragonix Technologies
Follow us on X (formerly twitter): @ParagonixSherpa
Find us on YouTube: Paragonix SherpaPak